Neurogeneticists have discovered a novel genetic mutation and associated buildup of toxic proteins in the brain -- a type of buildup distinct from amyloid or tau, proteins that have long been the ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

Enter SynPull, a new synaptosome imaging method developed by David Klenerman, John Danial, and colleagues at the University of Cambridge, England. SynPull combines single-molecule pull-down of ...

Researchers at the University of Pittsburgh have devised a biomarker test that can spot small amounts of clumping tau protein in the brain and cerebrospinal fluid, which lead to Alzheimer's disease.

At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and ...

The root causes of most forms of Alzheimer's disease largely remain a mystery. Now, researchers have revealed a new piece of the puzzle.

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

The variant causes a person's brain to accumulate beta amyloid and phosphorylated tau proteins, the hallmarks of Alzheimer's. When Whitney turned 60 and still had no symptoms, he assumed he didn't ...

Scientists from Brigham and Women’s Hospital have now identified a new protein that may contribute to the disease.

The variant causes a person’s brain to accumulate beta amyloid and phosphorylated tau proteins, the hallmarks of Alzheimer’s. When Whitney turned 60 and still had no symptoms, he assumed he didn’t ...